Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Serra P, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B, DeCensi A. Lazzeroni M, et al. Among authors: gallerani e. J Clin Oncol. 2023 Jun 10;41(17):3116-3121. doi: 10.1200/JCO.22.02900. Epub 2023 Mar 14. J Clin Oncol. 2023. PMID: 36917758 Clinical Trial.
Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence.
Zambelli A, Gallerani E, Garrone O, Pedersini R, Rota Caremoli E, Sagrada P, Sala E, Cazzaniga ME. Zambelli A, et al. Among authors: gallerani e. Crit Rev Oncol Hematol. 2023 Nov;191:104104. doi: 10.1016/j.critrevonc.2023.104104. Epub 2023 Sep 1. Crit Rev Oncol Hematol. 2023. PMID: 37659765 Free article. Review.
Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19.
Dallan B, Proietto D, De Laurentis M, Gallerani E, Martino M, Ghisellini S, Zurlo A, Volpato S, Govoni B, Borghesi M, Albanese V, Appay V, Bonnini S, Llewellyn-Lacey S, Pacifico S, Grumiro L, Brandolini M, Semprini S, Sambri V, Ladell K, Parry HM, Moss PAH, Price DA; RIV Study Group; Caputo A, Gavioli R, Nicoli F. Dallan B, et al. Among authors: gallerani e. Nat Aging. 2024 Aug;4(8):1121-1136. doi: 10.1038/s43587-024-00644-w. Epub 2024 Jun 25. Nat Aging. 2024. PMID: 38918602
New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies.
Guedes RA, Grilo JH, Carvalho AN, Fernandes PMP, Ressurreição AS, Brito V, Santos AO, Silvestre S, Gallerani E, Gama MJ, Gavioli R, Salvador JAR, Guedes RC. Guedes RA, et al. Among authors: gallerani e. Pharmaceuticals (Basel). 2023 Aug 2;16(8):1096. doi: 10.3390/ph16081096. Pharmaceuticals (Basel). 2023. PMID: 37631011 Free PMC article.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Partridge AH, et al. N Engl J Med. 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. N Engl J Med. 2023. PMID: 37133584 Free PMC article. Clinical Trial.
77 results